News for Avidity Biosciences, Inc. (RNA)

Summary Avidity Biosciences Inc (RNA), a biopharmaceutical company specializing in RNA therapeutics, announced its participation in Rare Disease Day on February

Strengths: Innovative AOC platform and robust pipeline with potential for significant market impact.Weaknesses: Lack of commercialization experience and high R

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 4.76% and 29.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

On February 27, 2025, Avidity Biosciences Inc (RNA), a leader in RNA therapeutics, announced its financial results for the fourth quarter of 2024. The company h

PR NewswireSAN DIEGO, Feb. 27, 2025 Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong

Revenue: $3.0 million for Q4 2024, surpassing the estimated $1.53 million.Net Loss: $102.3 million for Q4 2024, compared to $60.4 million in Q4 2023, reflectin

Avidity Biosciences Inc (RNA), a leading biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCsâ„¢), announced on February 25

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to muscle and heart cells. Learn more on RNA stock here.

Avidity Biosciences Inc (RNA), a leading biopharmaceutical company focused on RNA therapeutics, announced on February 21, 2025, the granting of non-qualified st

On December 31, 2024, Janus Henderson Group PLC executed a significant transaction by acquiring an additional 2,156,844 shares of Avidity Biosciences Inc, bring

On December 31, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) made a significant move by acquiring an additional 136,463 shares of Elutia Inc, a c

Avidity Biosciences director sells $53,536 in stock

Avidity Biosciences' chief medical officer sells shares totaling $112,856

Avidity Biosciences Inc (RNA), a San Diego-based biopharmaceutical company specializing in RNA therapeutics, announced on January 20, 2025, the granting of a no

PR NewswireSAN DIEGO, Jan. 20, 2025 SAN DIEGO, Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Avidity Biosciences, Inc.

On January 7, 2025, RTW INVESTMENTS, LP (Trades, Portfolio) made a strategic move by acquiring additional shares in Allurion Technologies Inc (ALUR). This trans

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where Avidity Biosciences, Inc.